News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
67,431 Results
Type
Article (4925)
Company Profile (32)
Press Release (62473)
Multimedia
Podcasts (8)
Webinars (1)
Section
Business (20156)
Career Advice (104)
Deals (2389)
Drug Delivery (16)
Drug Development (6736)
Employer Resources (8)
FDA (1163)
Job Trends (1690)
News (28310)
Policy (2302)
Tag
2025 Best Places to Work (5)
2026 Best Places to Work (3)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Genetown Standard (1)
Academia (548)
Accelerated approval (10)
ADA (6)
Adcomms (1)
Allergies (9)
Alliances (6786)
ALS (35)
Alzheimer's disease (200)
Antibody-drug conjugate (ADC) (70)
Approvals (1259)
Artificial intelligence (242)
ASCO (68)
Autoimmune disease (43)
Automation (21)
Bankruptcy (26)
Belgium (3)
Best Places to Work (1518)
BIO (8)
Biologics (10)
BIOSECURE Act (12)
Biosimilars (19)
BioSpace Insights (19)
Biotechnology (25)
Bispecific (3)
Bladder cancer (36)
Brain cancer (17)
Breast cancer (325)
Cancer (1462)
Cardiovascular disease (49)
Career advice (109)
Career pathing (5)
CAR-T (62)
CDC (4)
CDMO (25)
Celiac Disease (2)
Cell-line development (2)
Cell therapy (179)
Cervical cancer (7)
Clinical research (5756)
Collaboration (487)
Commercialization (2)
Compensation (63)
Complete response letters (4)
COVID-19 (309)
CRISPR (64)
C-suite (195)
Cystic fibrosis (24)
Data (1469)
Denatured (4)
Depression (13)
Dermatology (18)
Diabetes (50)
Diagnostics (1900)
Digital health (6)
Diversity, equity & inclusion (4)
Drug discovery (88)
Drug pricing (11)
Drug shortages (1)
Duchenne muscular dystrophy (34)
Earnings (5481)
Editorial (14)
Employer branding (1)
Employer resources (9)
ESMO (68)
Events (10459)
Executive appointments (166)
Eye disease (2)
FDA (1622)
Friedreich's ataxia (4)
Frontotemporal dementia (2)
Funding (271)
Gene editing (146)
Generative AI (16)
Gene therapy (157)
GLP-1 (90)
Government (456)
Guidances (51)
Healthcare (1929)
Hematology (30)
HIV (27)
Huntington's disease (12)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (29)
Immunology and inflammation (30)
Immuno-oncology (20)
Indications (32)
Infectious disease (365)
Inflammatory bowel disease (21)
Influenza (16)
Intellectual property (37)
Interviews (12)
IPO (1108)
IRA (2)
Job creations (212)
Job search strategy (95)
JPM (7)
Kidney cancer (3)
Kidney disease (22)
Labor market (7)
Layoffs (32)
Leadership (3)
Legal (388)
Licensing (7)
Liver cancer (13)
Longevity (11)
Lung cancer (199)
Lung diease (4)
Lymphoma (74)
Machine learning (15)
Management (4)
Manufacturing (129)
Marketing (2)
MASH (11)
Medical device (759)
Medtech (777)
Mergers & acquisitions (1419)
Metabolic disorders (135)
mRNA (49)
Multiple sclerosis (10)
Multispecific (1)
NASH (1)
Netherlands (1)
Neurodegenerative disease (64)
Neuropsychiatric disorders (11)
Neuroscience (411)
NextGen: Class of 2026 (568)
Non-profit (508)
Now hiring (7)
Obesity (67)
Opinion (69)
Ovarian cancer (26)
Pain (32)
Pancreatic cancer (76)
Parkinson's disease (66)
Partnered (6)
Patents (69)
Patient recruitment (89)
Patient selection (8)
Peanut (1)
People (6191)
Peptides (4)
Pharmaceutical (5)
Pharmacy benefit managers (2)
Phase 1 (2171)
Phase 2 (2527)
Phase 3 (1909)
Pipeline (1555)
Policy (36)
Postmarket research (122)
Preclinical (1134)
Press Release (26)
Prostate cancer (70)
Psychedelics (6)
Radioligand (1)
Radiopharmaceuticals (26)
Rare diseases (193)
Real estate (464)
Recruiting (2)
Regenerative medicine (3)
Regulatory (2086)
Reports (5)
Research institute (639)
Resumes & cover letters (8)
Rett syndrome (9)
RNA editing (4)
RSV (5)
Schizophrenia (19)
Series A (49)
Series B (33)
Sickle cell disease (36)
Special edition (1)
Spinal muscular atrophy (3)
Sponsored (6)
Startups (469)
Stem cells (2)
Supply chain (11)
Switzerland (2)
Tariffs (5)
The Weekly (4)
Vaccines (110)
Venture capital (16)
Weight loss (34)
Women's health (11)
Date
Today (16)
Last 7 days (80)
Last 30 days (386)
Last 365 days (3336)
2026 (3065)
2025 (3214)
2024 (4186)
2023 (4877)
2022 (6170)
2021 (6291)
2020 (5419)
2019 (4260)
2018 (3241)
2017 (3364)
2016 (3216)
2015 (3451)
2014 (2174)
2013 (1803)
2012 (1803)
2011 (1871)
2010 (1707)
Location
Africa (94)
Alabama (14)
Alaska (1)
Arizona (29)
Arkansas (1)
Asia (3790)
Australia (648)
California (2152)
Canada (285)
China (221)
Colorado (90)
Connecticut (191)
Delaware (47)
Europe (8542)
Florida (215)
Georgia (17)
Hawaii (2)
Idaho (9)
Illinois (166)
India (10)
Indiana (59)
Iowa (14)
Japan (84)
Kansas (7)
Kentucky (6)
Louisiana (5)
Maine (7)
Maryland (255)
Massachusetts (1388)
Michigan (25)
Minnesota (39)
Mississippi (1)
Missouri (23)
Montana (3)
Nebraska (6)
Nevada (15)
New Hampshire (3)
New Jersey (335)
New Mexico (12)
New York (535)
North Carolina (319)
North Dakota (10)
Northern California (1132)
Ohio (55)
Oklahoma (1)
Oregon (5)
Pennsylvania (195)
Rhode Island (12)
South America (88)
South Carolina (5)
Southern California (844)
Tennessee (27)
Texas (380)
United States (6675)
Utah (69)
Vermont (2)
Virginia (46)
Washington D.C. (5)
Washington State (130)
West Virginia (1)
Wisconsin (34)
67,431 Results for "ers genomics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
November 16, 2026
·
15 min read
Press Releases
FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
November 16, 2026
·
13 min read
Press Releases
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
In matched multi-center cohorts, Telo Genomics is expanding comparative evaluation of blood-based TELO-MRD against Adaptive Biotechnologies’ clonoSEQ next-generation sequencing MRD testing.
October 29, 2026
·
6 min read
Press Releases
Telo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells
Agreement with the University of Manitoba and Technion Research and Development Foundation Ltd. provides an option for a license that could expand Telo Genomics’ liquid-biopsy platform for cancer screening, diagnosis, treatment selection and disease monitoring.
November 18, 2026
·
6 min read
Press Releases
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
November 18, 2026
·
5 min read
Press Releases
Glioblastoma Foundation’s Genomic Testing & Research Laboratory Now Accepting Patient Samples for Genomic Testing
November 1, 2026
·
4 min read
Press Releases
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture
July 16, 2026
·
8 min read
Press Releases
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
October 8, 2026
·
4 min read
Press Releases
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
October 8, 2026
·
4 min read
Press Releases
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
August 12, 2026
·
6 min read
1 of 6,744
Next